A new study shows that there is a very limited regeneration of cells in the brain of patients diagnosed with multiple sclerosis (MS). These findings underline the importance of treating MS at an early stage of the disease progression when the affected cells can repair the damage as new ones do not replace them. The results are published in the journal Nature by researchers from Karolinska Institute and Uppsala University in Sweden.
Nerve cells in the brain communicate with one another through nerve fibers that form complex networks. Many nerve fibers are insulated by a casing of myelin, which contributes to the high-speed transmission of nerve impulses. Myelin is not created by the nerve cells but by another type of cells called oligodendrocytes.
MS is a disease caused by the body's immune system attacking the myelin and oligodendrocytes. This leads to deteriorated transmission of signals in the nerve fibers and can entail nerve cell death, a combination that causes severe neurological impairments and in severe cases the patient's death.
The disease progression in MS usually fluctuates between periods of deterioration and periods of remission. Studies in mice have shown that damaged myelin can be reformed and that this requires the generation of new oligodendrocytes that make the myelin. It has been assumed that periods of remission in MS patients are caused by newly formed oligodendrocytes replacing the lost myelin.
But in this study, a research group has been able to show that there is no regeneration of oligodendrocytes in MS patients in those areas where the myelin seems to have been reformed. Instead, it appears as if old oligodendrocytes that have survived the attack from the immune defense can form new myelin.
"We were highly surprised that humans proved to be so different from the animals that have been studied. In humans, there is very limited regeneration of oligodendrocytes, but they seem to have a greater capacity to contribute to repair," says Jonas Frisén, Professor at the Department of Cell and Molecular Biology at Karolinska Institute, who led the study.
These new findings indicate the importance of treating MS aggressively at an early stage of disease progression, to prevent the loss of oligodendrocytes.
"Since few oligodendrocytes are formed, it is important to save the ones you have as they can repair the damage caused by the disease," says Jonas Frisén.
To determine the age of the oligodendrocytes in the MS patients, the researchers measured the amount of the isotope carbon-14 from nuclear detonations during the cold war, which was stored in the cells' genome. Since the detonations ceased, there has been a gradual decrease of carbon-14, which acts as a type of date mark for when the cells were formed. Jonas Frisén's team developed this method of determining the age of a cell in the early 2000s.
The study was funded by the Swedish Research Council, the Swedish Cancer Society, the Tobias Foundation, the Strategic Research Foundation (SSF), the Knut and Alice Wallenberg Foundation, the European Research Council (ERC) and the Torsten Söderberg Foundation.